+

WO1997032989A3 - Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung - Google Patents

Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung Download PDF

Info

Publication number
WO1997032989A3
WO1997032989A3 PCT/DE1997/000447 DE9700447W WO9732989A3 WO 1997032989 A3 WO1997032989 A3 WO 1997032989A3 DE 9700447 W DE9700447 W DE 9700447W WO 9732989 A3 WO9732989 A3 WO 9732989A3
Authority
WO
WIPO (PCT)
Prior art keywords
transduction system
aav vector
same
recombinant aav
based transduction
Prior art date
Application number
PCT/DE1997/000447
Other languages
English (en)
French (fr)
Other versions
WO1997032989A2 (de
Inventor
Gerd Maass
Christoph Bogedain
Michael Hallek
Clemens Wendtner
Doris Michl
Original Assignee
Medigene Gmbh
Gerd Maass
Christoph Bogedain
Michael Hallek
Clemens Wendtner
Doris Michl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Gmbh, Gerd Maass, Christoph Bogedain, Michael Hallek, Clemens Wendtner, Doris Michl filed Critical Medigene Gmbh
Priority to US09/142,289 priority Critical patent/US6207453B1/en
Priority to EP97918010A priority patent/EP0891429A2/de
Priority to JP9531353A priority patent/JP2000506726A/ja
Publication of WO1997032989A2 publication Critical patent/WO1997032989A2/de
Publication of WO1997032989A3 publication Critical patent/WO1997032989A3/de
Priority to US09/773,302 priority patent/US6440742B1/en
Priority to US10/218,280 priority patent/US20020192826A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Transduktionssystem, umfassend (a) einen, eine Fremd-DNA enthaltenden, rep-negativen AAV-Vektor, und (b) ein ein AAV-Rep-Protein bereitstellendes Mittel. Ferner umfaßt die Erfindung die Verwendung des Transduktionssystems.
PCT/DE1997/000447 1996-03-06 1997-03-06 Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung WO1997032989A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/142,289 US6207453B1 (en) 1996-03-06 1997-03-06 Recombinant AAV vector-based transduction system and use of same
EP97918010A EP0891429A2 (de) 1996-03-06 1997-03-06 Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung
JP9531353A JP2000506726A (ja) 1996-03-06 1997-03-06 組換えａａｖベクターに基づく形質導入系およびその使用
US09/773,302 US6440742B1 (en) 1996-03-06 2001-01-31 Recombinant AAV vector-based transduction system and use of same
US10/218,280 US20020192826A1 (en) 1996-03-06 2002-08-12 Recombinant AAV vector-based transduction system and use of same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19608753A DE19608753C1 (de) 1996-03-06 1996-03-06 Transduktionssystem und seine Verwendung
DE19608753.8 1996-03-06

Publications (2)

Publication Number Publication Date
WO1997032989A2 WO1997032989A2 (de) 1997-09-12
WO1997032989A3 true WO1997032989A3 (de) 1998-01-15

Family

ID=7787450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000447 WO1997032989A2 (de) 1996-03-06 1997-03-06 Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung

Country Status (5)

Country Link
US (3) US6207453B1 (de)
EP (1) EP0891429A2 (de)
JP (1) JP2000506726A (de)
DE (1) DE19608753C1 (de)
WO (1) WO1997032989A2 (de)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
DE60334250D1 (de) * 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
US20070032570A1 (en) * 2003-11-11 2007-02-08 Canon Kabushiki Kaisha Ink comprising a block copolymer dispersing agent having a hydrophilic and a hydrophobic segment and an ink-applying process and apparatus using the same
US20050281786A1 (en) * 2004-06-18 2005-12-22 David Poulsen AAV mediated gene delivery to cochlear cells
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
EP3597741A1 (de) 2012-04-27 2020-01-22 Duke University Genetische korrektur mutierter gene
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
DK4219687T3 (da) 2014-04-23 2024-10-28 Juno Therapeutics Inc Fremgangsmåder til isolering, dyrkning og genmanipulering af immuncellepopulationer til adoptiv terapi
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
ES2879612T3 (es) 2014-10-20 2021-11-22 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva
PL3215601T3 (pl) 2014-11-05 2020-11-02 Juno Therapeutics, Inc. Sposoby transdukcji i przetwarzania komórek
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
KR20170128234A (ko) 2015-01-16 2017-11-22 주노 쎄러퓨티크스 인코퍼레이티드 Ror1에 특이적인 항체 및 키메라 항원 수용체
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
JP6949728B2 (ja) 2015-05-29 2021-10-13 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
WO2017079703A1 (en) 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
EA201891317A3 (ru) 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MA43378A (fr) 2015-12-03 2018-10-10 Juno Therapeutics Inc Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
CN116041538A (zh) 2015-12-03 2023-05-02 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
ES2901795T3 (es) 2015-12-04 2022-03-23 Juno Therapeutics Inc Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
WO2017161212A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
WO2017161208A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
AU2017238218B2 (en) 2016-03-22 2024-05-02 Seattle Children's Hospital (dba Seattle Children's Research Institute) Early intervention methods to prevent or ameliorate toxicity
CN116850305A (zh) 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法
EP4011381A1 (de) 2016-06-03 2022-06-15 Memorial Sloan-Kettering Cancer Center Adoptive zelltherapien als frühe behandlungsoptionen
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US12214056B2 (en) 2016-07-19 2025-02-04 Duke University Therapeutic applications of CPF1-based genome editing
MA45779A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Polypeptides immunomdulateurs et compositions et procédés associés
BR112019001327A2 (pt) 2016-07-29 2019-04-30 Juno Therapeutics Inc anticorpos anti-idiotípicos e métodos relacionados
CN109890952A (zh) 2016-09-12 2019-06-14 朱诺治疗学股份有限公司 灌注生物反应器袋装配
US20190298771A1 (en) 2016-09-28 2019-10-03 Atossa Genetics Inc. Methods of adoptive cell therapy
MX2019003768A (es) 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
SG11201903282TA (en) 2016-10-13 2019-05-30 Juno Therapeutics Inc Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CN110139669A (zh) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
US20190292246A1 (en) 2016-11-03 2019-09-26 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia imhibitor
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
WO2018102787A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
BR112019011025A2 (pt) 2016-12-03 2019-10-08 Juno Therapeutics Inc métodos para modulação de células t car
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
CN110418802A (zh) 2017-01-20 2019-11-05 朱诺治疗学有限公司 细胞表面缀合物及相关的细胞组合物和方法
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
CN110582287A (zh) 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 与在细胞疗法中给药有关的组合物、制品和方法
AU2018234640C9 (en) 2017-03-14 2024-10-03 Juno Therapeutics, Inc. Methods for cryogenic storage
JOP20180027A1 (ar) 2017-03-28 2019-01-30 Cell Design Labs Inc بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
EP3607319A1 (de) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Manipulierte zellen, die prostataspezifisches membranantigen (psma) oder eine modifizierte form davon exprimieren, und zugehörige verfahren
AU2018251188A1 (en) 2017-04-14 2019-10-31 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
CA3060526A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
BR112019022893A2 (pt) 2017-05-01 2020-05-19 Juno Therapeutics Inc combinação de uma terapia celular e um composto imunomodulatório
MX2019014268A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
AU2018275891B2 (en) 2017-06-02 2025-02-27 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
LT3538645T (lt) 2017-06-20 2021-04-26 Institut Curie Suv39h1 atžvilgiu defektyvios imuninės ląstelės
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
BR112020001719A2 (pt) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagentes para expansão de células que expressam receptores recombinantes
CA3070575A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
BR112020001605A2 (pt) 2017-08-09 2020-08-11 Juno Therapeutics Inc métodos para produzir composições de células geneticamente modificadas e composições relacionadas
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
FI3703750T3 (fi) 2017-11-01 2025-02-07 Juno Therapeutics Inc B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
EP3704251A2 (de) 2017-11-01 2020-09-09 Editas Medicine, Inc. Verfahren, zusammensetzungen und komponenten zur crispr-cas9-editierung von tgfbr2 in t-zellen für die immuntherapie
EP3704229B1 (de) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Verfahren zur herstellung einer t-zell-zusammensetzung
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019090202A1 (en) 2017-11-06 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
KR20200095487A (ko) 2017-11-10 2020-08-10 주노 쎄러퓨티크스 인코퍼레이티드 폐쇄-시스템 극저온 용기
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
EP3720949A1 (de) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Serumfreie medienformulierung zur anzucht von zellen und verwendungsverfahren dafür
US20200384025A1 (en) 2017-12-08 2020-12-10 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
JP2021505615A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 細胞療法および関連方法のための表現型マーカー
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
US20190194617A1 (en) 2017-12-22 2019-06-27 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
US20210069246A1 (en) 2018-01-31 2021-03-11 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
WO2019170845A1 (en) 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
EP3768700A1 (de) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimäre transmembranproteine und verwendungen davon
MX2020010459A (es) 2018-04-05 2021-01-20 Juno Therapeutics Inc Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CN112805378A (zh) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 用于评估整合核酸的方法
SG11202102108QA (en) 2018-09-11 2021-04-29 Juno Therapeutics Inc Methods for mass spectrometry analysis of engineered cell compositions
CN113166202B (zh) 2018-10-12 2024-09-13 治疗调适公司 包括β-磷酸三钙-结合序列的多肽及其用途
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
KR20210102888A (ko) 2018-11-01 2021-08-20 주노 쎄러퓨티크스 인코퍼레이티드 Ｇ 단백질 결합 수용체 ｃ 클래스 5 그룹 ｄ 멤버(ｇｐｒｃ5ｄ)에 특이적인 키메라 항원 수용체
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
JP7604366B2 (ja) 2018-11-06 2024-12-23 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作されたｔ細胞を作製するための方法
EP3876958A1 (de) 2018-11-08 2021-09-15 Juno Therapeutics, Inc. Verfahren und kombinationen zur behandlung und t-zell-modulation
US20220008465A1 (en) 2018-11-16 2022-01-13 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
ES2981569T3 (es) 2018-11-30 2024-10-09 Juno Therapeutics Inc Métodos de tratamiento usando terapia celular adoptiva
BR112021010120A2 (pt) 2018-11-30 2021-08-31 Juno Therapeutics, Inc. Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
PE20212198A1 (es) 2019-01-29 2021-11-16 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
EP3962520A1 (de) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Zellen, die einen rekombinanten rezeptor aus einem modifizierten tgfbr2-locus exprimieren, verwandte polynukleotide und verfahren
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
CA3139965A1 (en) 2019-06-07 2020-12-10 Ivie AIFUWA Automated t cell culture
US20220249637A1 (en) 2019-06-12 2022-08-11 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
US12109235B2 (en) 2019-06-21 2024-10-08 Kite Pharma, Inc. TGF-beta receptors and methods of use
EP4003407A1 (de) 2019-07-23 2022-06-01 Mnemo Therapeutics Suv39h1-deffiziente immunzellen
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
US20220392613A1 (en) 2019-08-30 2022-12-08 Juno Therapeutics, Inc. Machine learning methods for classifying cells
US20220333132A1 (en) 2019-09-03 2022-10-20 Sana Blotechnology, Inc. Cd24-associated particles and related methods and uses thereof
JPWO2021070956A1 (de) 2019-10-11 2021-04-15
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
EP4055383A1 (de) 2019-11-05 2022-09-14 Juno Therapeutics, Inc. Verfahren zur bestimmung von eigenschaften therapeutischer t-zellzusammensetzungen
EP4054623A1 (de) 2019-11-07 2022-09-14 Juno Therapeutics, Inc. Kombination aus einer t-zelltherapie und (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidin-2,6-dion
US20230192869A1 (en) 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
WO2021113770A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
JP2023513434A (ja) 2020-01-24 2023-03-31 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法
AU2021220875A1 (en) 2020-02-12 2022-09-29 Juno Therapeutics, Inc. CD19-directed chimeric antigen receptor T cell compositions and methods and uses thereof
AU2021219764A1 (en) 2020-02-12 2022-09-01 Juno Therapeutics, Inc. BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
CA3179800A1 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
EP4135750A4 (de) 2020-04-15 2024-08-21 Theradaptive, Inc. Zusammensetzungen und verfahren zur gezielten therapeutischen freisetzung in knochen
AU2021263765A1 (en) 2020-04-28 2022-12-01 Juno Therapeutics, Inc. Combination of BCMA-directed T cell therapy and an immunomodulatory compound
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
KR20230074713A (ko) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Socs1에 결함이 있는 면역 세포
KR20230095918A (ko) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
WO2022047316A1 (en) 2020-08-28 2022-03-03 Sana Biotechnology, Inc. Modified anti-viral binding agents
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
MX2023008081A (es) 2021-01-11 2023-09-12 Sana Biotechnology Inc Uso de vectores virales dirigidos a cd8.
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
AU2022252220A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
EP4322959A2 (de) 2021-04-16 2024-02-21 Celgene Corporation Kombinationstherapien mit bcma-gerichteter t-zelltherapie
WO2022234009A2 (en) 2021-05-06 2022-11-10 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
EP4346912A1 (de) 2021-05-25 2024-04-10 Institut Curie Myeloidzellen, die bcl2 überexprimieren
EP4377459A2 (de) 2021-07-30 2024-06-05 Tune Therapeutics, Inc. Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
JP2024528981A (ja) 2021-08-04 2024-08-01 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４標的化ウイルスベクターの使用
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
KR20240112994A (ko) 2021-11-03 2024-07-19 셀진 코포레이션 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4463135A2 (de) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Verfahren zur ex-vivo-dosierung und -verabreichung von lipidpartikeln oder viralen vektoren sowie entsprechende systeme und verwendungen
EP4463548A1 (de) 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur programmierung von t-zell-phänotypen durch gezielte genaktivierung
EP4463549A2 (de) 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur programmierung von t-zell-phänotypen durch gezielte genunterdrückung
EP4472646A1 (de) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Auf cd3 abzielende lentivirale vektoren und verwendungen davon
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
KR20240150790A (ko) 2022-02-22 2024-10-16 주노 쎄러퓨티크스 인코퍼레이티드 프로테이나제 3 (pr3) 키메라 자가항체 수용체 t 세포 및 관련 방법 및 용도
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023201133A1 (en) 2022-04-14 2023-10-19 Board Of Regents Of The University Of Nebraska Cell therapy for alzheimer's disease
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (de) 2022-05-20 2023-11-22 Mnemo Therapeutics Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
EP4532695A1 (de) 2022-05-25 2025-04-09 Celgene Corporation Verfahren zur herstellung von t-zelltherapien
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
EP4543923A1 (de) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Behandlungsverfahren für die zweite therapie von cd19-gezielten car-t-zellen
KR20250044484A (ko) 2022-06-24 2025-03-31 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
IL318416A (en) 2022-08-05 2025-03-01 Juno Therapeutics Inc Chimeric antigen receptors specific for GPRC5D and BCMA
WO2024040254A2 (en) 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
IL318749A (en) 2022-08-26 2025-04-01 Juno Therapeutics Inc Delta-like ligand 3 (DLL3)-specific chimeric antigen receptors and antibodies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021808A1 (de) * 1993-03-19 1994-09-29 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von krebsvakzinen
WO1995014771A1 (en) * 1993-11-24 1995-06-01 GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health Vector systems for the generation of adeno-associated virus particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US6342390B1 (en) * 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021808A1 (de) * 1993-03-19 1994-09-29 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von krebsvakzinen
WO1995014771A1 (en) * 1993-11-24 1995-06-01 GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health Vector systems for the generation of adeno-associated virus particles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIORINI J.A. ET AL.: "High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors.", HUMAN GENE THERAPY, vol. 6, no. 12, December 1995 (1995-12-01), pages 1531 - 1541, XP002036175 *
GOSSEN M ET AL: "TIGHT CONTROL OF GENE EXPRESSION IN MAMMALIAN CELLS BY TETRACYCLINE-RESPONSIVE PROMOTERS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 12, 15 June 1992 (1992-06-15), pages 5547 - 5551, XP000564458 *
KOTIN R.M.: "Prospects for the use of adeno-associated virus as a vector for human gene therapy.", HUMAN GENE THERAPY, vol. 5, no. 7, 1994, pages 793 - 801, XP002036176 *
NATSOULIS G ET AL: "A SYSTEM FOR SPECIFICALLY TARGETING GENES TO CHROMOSOME", BLOOD, vol. 86, no. 10, SUPPL. 01, 15 November 1995 (1995-11-15), pages 236A, XP000607611 *

Also Published As

Publication number Publication date
US20020192826A1 (en) 2002-12-19
US6207453B1 (en) 2001-03-27
US20020028514A1 (en) 2002-03-07
US6440742B1 (en) 2002-08-27
EP0891429A2 (de) 1999-01-20
DE19608753C1 (de) 1997-06-26
JP2000506726A (ja) 2000-06-06
WO1997032989A2 (de) 1997-09-12

Similar Documents

Publication Publication Date Title
WO1997032989A3 (de) Transduktionssystem beruhend auf rekombinantem aav-vektor und seine verwendung
IL122403A0 (en) Recombinant dna vector comprising aav nucleic acid sequences
AU9319198A (en) Methods and vector constructs useful for production of recombinant aav
ZA976326B (en) Analogs of cationic proteins.
ZA96632B (en) Virtual point of service (pos) terminal
PT1009808E (pt) Métodos para a produção de preparações de elevado título de vectores de aav recombinante isentas de auxiliar
ZA975943B (en) Aqueous formulations of peptides.
AU7332198A (en) Lentivirus based vector and vector system
GB9505478D0 (en) Personal navigation system
AU5264498A (en) Genes encoding telomerase proteins
EP0738319A4 (de) Reinigung von retroviralen Vektoren
WO1999020773A3 (en) TRANSCRIPTIONALLY-ACTIVATED AAV INVERTED TERMINAL REPEATS (ITRs) FOR USE WITH RECOMBINANT AAV VECTORS
ZA9710288B (en) Novel genes encoding telomerase proteins.
AU5057898A (en) Novel constructs and vectors for the targeted and inducible expression of genes
AUPN861496A0 (en) Lytic peptides
AU5652396A (en) Glucose-inducible recombinant viral vector
WO1992003559A3 (de) Testsystem zur aktivitätsüberprüfung viraler proteinasen
AU8450298A (en) Heterologous expression of proteins by "rescued" vector comprising an intron
WO1998018950A3 (de) Aav-dna mit helfervirus-sequenzen
AU3718595A (en) Transduction of genes into human hematopoietic stem cells using recombinant adeno-associated viral vectors
GB9614615D0 (en) Diagnosis of pre-eclampsia
WO1998027206A3 (fr) Polypeptides de la famille 'basic helix-loop-helix' bhlh, sequences d'acides nucleiques correspondantes
IL121676A0 (en) Parvovirus vectors
AU4221597A (en) Plant-origin regulator protein and nucleic acid encoding the same
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997918010

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997918010

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09142289

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1997918010

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载